3,555 reports of this reaction
1.3% of all ADALIMUMAB FKJP reports
#19 most reported adverse reaction
PSORIATIC ARTHROPATHY is the #19 most commonly reported adverse reaction for ADALIMUMAB FKJP, manufactured by Biocon Biologics Inc. There are 3,555 FDA adverse event reports linking ADALIMUMAB FKJP to PSORIATIC ARTHROPATHY. This represents approximately 1.3% of all 281,217 adverse event reports for this drug.
Patients taking ADALIMUMAB FKJP who experience psoriatic arthropathy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIATIC ARTHROPATHY is a less commonly reported adverse event for ADALIMUMAB FKJP, but still significant enough to appear in the safety profile.
In addition to psoriatic arthropathy, the following adverse reactions have been reported for ADALIMUMAB FKJP:
The following drugs have also been linked to psoriatic arthropathy in FDA adverse event reports:
PSORIATIC ARTHROPATHY has been reported as an adverse event in 3,555 FDA reports for ADALIMUMAB FKJP. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIATIC ARTHROPATHY accounts for approximately 1.3% of all adverse event reports for ADALIMUMAB FKJP, making it a notable side effect.
If you experience psoriatic arthropathy while taking ADALIMUMAB FKJP, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.